Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.
Shi J, Chen G, Wang H, Wang X, Han B, Li K, Wang Q, Zhang L, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Liu Z.
Shi J, et al. Among authors: wang h, wang x, wang z, wang q.
Thorac Cancer. 2021 Sep;12(17):2345-2351. doi: 10.1111/1759-7714.14076. Epub 2021 Jul 17.
Thorac Cancer. 2021.
PMID: 34273139
Free PMC article.
Clinical Trial.